Pelthos Therapeutics Inc. (PTHS)
| Market Cap | 90.10M +852.3% |
| Revenue (ttm) | 16.80M |
| Net Income | -43.32M |
| EPS | -23.04 |
| Shares Out | 3.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,263 |
| Open | 25.30 |
| Previous Close | 25.50 |
| Day's Range | 25.28 - 26.85 |
| 52-Week Range | 9.00 - 54.29 |
| Beta | 3.33 |
| Analysts | Strong Buy |
| Price Target | 54.17 (+101.75%) |
| Earnings Date | May 14, 2026 |
About PTHS
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestati... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PTHS stock is "Strong Buy." The 12-month stock price target is $54.17, which is an increase of 101.75% from the latest price.
News
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patie...
Pelthos Therapeutics says John Gay to succeed Francis Knuettel II as CFO
Pelthos Therapeutics (PTHS) announced John Gay has been appointed CFO, effective April 10. Gay succeeds Francis Knuettel II, who served as Pelthos’ CFO since July 2025. Gay has served as…
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target Pelthos is emerging as a commercial launch story, with early script trends indicating...
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target
Pelthos Therapeutics doses first patient in CT2000 trial
Pelthos Therapeutics (PTHS) announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos’ subsidiary Channel Pharmac...
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease
Pelthos Therapeutics Transcript: The 38th Annual Roth Conference
Pelthos has rapidly grown ZELSUVMI prescriptions and revenue, with strong payer coverage and a robust cash position. Upcoming launches of Xepi and Xeglyze will leverage existing sales channels, while patent protection and proprietary manufacturing support long-term growth.
Pelthos Therapeutics Inc trading resumes
11:13 EDT Pelthos Therapeutics (PTHS) Inc trading resumes
Pelthos Therapeutics Inc trading halted, volatility trading pause
11:08 EDT Pelthos Therapeutics (PTHS) Inc trading halted, volatility trading pause
Pelthos Therapeutics price target raised to $62 from $60 at Oppenheimer
Oppenheimer analyst Jeff Jones raised the firm’s price target on Pelthos Therapeutics (PTHS) to $62 from $60 and keeps an Outperform rating on the shares after the company reported year-end…
Pelthos Therapeutics Earnings Call Transcript: Q4 2025
Q4 2025 saw strong revenue growth and reduced losses, driven by ZELSUVMI's rapid uptake and expanded coverage. Two FDA-approved product acquisitions and new financing position the company for continued growth and expected profitability by year-end 2026.
Pelthos Therapeutics reports Q4 EPS ($6.87) vs. ($3.19) last year
Reports Q4 Zelsuvmi revenue $9.1M vs. $7.1M vs. last year. CEO Scott Plesha commented, “We are delighted with the growth of Zelsuvmi in our second quarter of commercialization despite the…
Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results
ZELSUVMI ™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...
Pelthos Therapeutics to Present at 38th Annual ROTH Conference
DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pat...
Pelthos Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler analyst David Amsellem initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $48 price target The company’s lead asset Zelsuvmi is a recently-launched novel nit...
Pelthos Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Recent commercial launch of ZELSUVMI for pediatric molluscum contagiosum has exceeded expectations, driving strong revenue growth and rapid prescriber adoption. Portfolio expansion with Xepi and Xeglyze leverages existing infrastructure, while robust patent protection and financial position support future growth.
Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital
Roth Capital lowered the firm’s price target on Pelthos Therapeutics (PTHS) to $55 from $57 and keeps a Buy rating on the shares. The firm has adjusted its Zelsuvmi revenue…
Pelthos Therapeutics files $200M mixed securities shelf
16:47 EST Pelthos Therapeutics (PTHS) files $200M mixed securities shelf
Pelthos Therapeutics price target raised to $60 from $57 at Oppenheimer
Oppenheimer raised the firm’s price target on Pelthos Therapeutics (PTHS) to $60 from $57 and keeps an Outperform rating on the shares. The firm is updating its ZELSUVMI forecast and…
Horizon Technology provides $50M loan facility to Pelthos Therapeutics
Horizon Technology (HRZN) “announced it has provided a $50 million venture loan facility to Pelthos Therapeutics (PTHS), with an initial funding of $30 million, and up to $20 million to…
Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics
FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million ven...
Pelthos Therapeutics secures up to $50M senior secured term loan
Pelthos Therapeutics (PTHS) has secured financing from Horizon Technology Finance Corporation (HRZN), an affiliate of Monroe Capital, with an initial funding of $30M, and up to $20M to support future…
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance
The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum conta...
Pelthos Therapeutics acquires Xeglyze topical treatment for $1.8M
Pelthos Therapeutics (PTHS) has acquired Xeglyze from Hatchtech for $1.8M. Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and…
Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice
DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet pati...